VWC2 Increases Bone Formation Through Inhibiting Activin Signaling

Area of Science:

• Biochemistry
• Cell Biology
• Bone Biology

Background:

• VWC2 (von Willebrand factor C domain containing 2), also known as Brorin, is a novel cysteine knot protein.
• Previous studies suggested Brorin acts as a bone morphogenetic protein (BMP) antagonist, but its precise function in bone formation was unclear.

Purpose of the Study:

• To investigate the role of VWC2 in bone formation.
• To identify VWC2 binding partners within the transforming growth factor (TGF)-β superfamily.
• To elucidate the molecular mechanism by which VWC2 influences osteoblast activity and bone development.

Main Methods:

• Bioinformatics analysis to identify VWC2.
• Protein binding assays to determine VWC2 interaction partners.
• Gene expression analysis and immunolocalization of VWC2 in osteoblasts.
• Cell culture experiments using MC3T3-E1 cells and primary osteoblasts to assess VWC2 effects on Activin A signaling.
• Ex vivo cranial bone organ culture to evaluate VWC2's impact on bone morphometrics.

Main Results:

• VWC2 binds to the βA subunit of activin, not BMPs.
• VWC2 expression is upregulated during osteoblast differentiation and localized in bone matrix.
• VWC2 inhibits Activin A-induced Smad2 phosphorylation in osteoblasts.
• VWC2 treatment restored bone morphometric parameters in organ cultures and reversed negative effects of Activin A on osteoblast growth, differentiation, and mineralization.

Conclusions:

• VWC2 is a novel secretory protein that promotes bone formation.
• VWC2 exerts its bone-promoting effects by inhibiting the Activin A-Smad2 signaling pathway.
• VWC2 represents a potential therapeutic target for bone-related disorders.